#ESMO26| 馃珌Una nueva combinaci贸n, la de #tarlatamab y #durvalumab, reduce el riesgo de muerte en un 58% en #c谩ncer de pulm贸n microc铆tico.
@myESMO https://www.diariomedico.com/medicina/oncologia/tarlatamab-mas-durvalumab-nueva-quiniela-ganadora-cancer-pulmon-microcitico.html?utm_medium=Social&utm_source=Twitter#Echobox=1792853965
67 views 路 0 likes 路 0 reposts 路 0 replies
Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.orgCytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgSource: Diario M茅dico 路 x.com